Terbinafine 250 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Dermatophyte Infections (Tinea/Ringworm)

• Clotrimazole
• Ketoconazole
• Clotrimazole 1% cream
• Ketoconazole 2% cream

What Terbinafine 250 mg tabs is approved for (FDA label)

Terbinafine tablets, USP are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. Terbinafine tablets are an allylamine antifungal indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 19, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Terbinafine 250 mg tabs (FDA label)

Terbinafine tablets, 250 mg are supplied as white, round, flat faced beveled edge tablets debossed with IG on one side and 209 on the other. Tablet, 250 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 18b16aad-1877-4b07-b532-f0ef4843af91. SPL document ID: e3db8f4b-ea51-41b6-859e-ad91677aaf73. Label effective date: September 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Terbinafine 250 mg tabs (FDA label)

Common (greater than 2% of patients treated with terbinafine tablets) reported adverse events include headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbance, nausea, abdominal pain, and flatulence. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 18b16aad-1877-4b07-b532-f0ef4843af91. SPL document ID: e3db8f4b-ea51-41b6-859e-ad91677aaf73. Label effective date: September 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Terbinafine 250 mg tabs (FDA label)

Terbinafine tablets are contraindicated in patients with: • History of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see Adverse Reactions (6.2) ] • Chronic or active liver disease [see Warnings and Precautions (5.1) ] Chronic or active liver disease. ( 4 ) History of allergic reaction to oral terbinafine because of the risk of anaphylaxis. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 18b16aad-1877-4b07-b532-f0ef4843af91. SPL document ID: e3db8f4b-ea51-41b6-859e-ad91677aaf73. Label effective date: September 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Terbinafine 250 mg tabs (FDA label)

Liver failure, sometimes leading to liver transplant or death, has occurred with the use of oral terbinafine. Obtain pretreatment serum transaminases. Prior to initiating treatment and periodically during therapy, assess liver function tests. Discontinue terbinafine tablets if liver injury develops. ( 5.1 ) Taste disturbance, including taste loss, has been reported with the use of terbinafine tablets. Taste disturbance can be severe, may be prolonged, or may be permanent. Discontinue terbinafine tablets if taste disturbance occurs. ( 5.2 ) Smell disturbance, including loss of smell, has been reported with the use of terbinafine tablets. Smell disturbance may be prolonged, or may be permanent. Discontinue terbinafine tablets if smell disturbance occurs. ( 5.3 ) Depressive symptoms have been reported with terbinafine use. Prescribers should be alert to the development of depressive symptoms. ( 5.4 ) Severe neutropenia has been reported.

Source: FDA prescribing information (DailyMed). Set ID: 18b16aad-1877-4b07-b532-f0ef4843af91. SPL document ID: e3db8f4b-ea51-41b6-859e-ad91677aaf73. Label effective date: September 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Terbinafine 250 mg tabs (FDA label)

Terbinafine is an inhibitor of CYP450 2D6 isozyme and has an effect on metabolism of desipramine. Drug interactions have also been noted with cimetidine, fluconazole, cyclosporine, rifampin, and caffeine. ( 7.1 ) 7.1 Drug-Drug Interactions In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of terbinafine tablets should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in C max and a 5-fold increase in area under the curve (AUC).

Source: FDA prescribing information (DailyMed). Set ID: 18b16aad-1877-4b07-b532-f0ef4843af91. SPL document ID: e3db8f4b-ea51-41b6-859e-ad91677aaf73. Label effective date: September 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.